Phase 3 COPD Trial, Recruiting NCT06473701 Sponsor: Vejle Hospital Condition: COPD
Back to Copd

Phase 3 COPD Trial, Recruiting

NCT06473701
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have severe or very severe COPD (classified as GOLD stage 3 or 4)
  • People who still experience significant breathlessness even after receiving the best available standard treatment
  • People whose breathlessness is rated at level 3 or higher on a standard scale called the mMRC scale, meaning breathlessness that seriously limits daily activity
  • People aged 18 or older who are considered legally and mentally capable of making their own decisions
  • People who understand and speak Danish
  • People who are able to give written informed consent to participate
  • Women who could potentially become pregnant must have a negative pregnancy test before entering the trial
  • Fertile people who are sexually active must agree to use reliable contraception (such as an IUD, contraceptive pill, implant, patch, vaginal ring, or depot injection) throughout the treatment period and for 4 weeks after finishing

Who may not be able to join:

  • People who have had an active infection or a flare-up of their COPD within the last 30 days
  • People who have been regularly using THC or CBD products within the last 30 days
  • People whose life expectancy is estimated to be less than 3 months
  • People currently taking certain medications that strongly affect the way the body processes drugs (specifically, strong inhibitors or inducers of enzymes called CYP3A4, CYP2C9, or CYP2C19 — confirm specific medications with the trial site)
  • People with a significant medical or psychiatric condition that the trial doctor believes would put them at greater risk of harm during the study
  • People with a current or past history of substance misuse that the trial doctor considers too risky for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ole Hilberg, Prof., MD, Medical Department, Vejle Hospital

Phone: +45 79409055

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Vejle Hospital
Registry
ClinicalTrials.gov
Start date
26 February 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Difference in Numeric Rating Scale score of discomfort of daily breathlessness between active treatment and placebo; Difference in Numeric Rating Scale score of breathlessness interference of daily activities between active treatment and placebo; Correlation between breathlessness rated on a daily numeric rating scale in relation to amount of THC blood level of the active treatment period; Correlation between breathlessness interference of daily activities rated on a numeric rating scale in relation to amount of THC blood level of the active treatment period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov